ABCG2 p.Asn557Glu

Predicted by SNAP2: A: D (91%), C: D (91%), D: D (95%), E: D (95%), F: D (95%), G: D (95%), H: D (95%), I: D (91%), K: D (95%), L: D (91%), M: D (91%), P: D (95%), Q: D (95%), R: D (95%), S: D (95%), T: D (91%), V: D (91%), W: D (95%), Y: D (91%),
Predicted by PROVEAN: A: D, C: D, D: D, E: D, F: D, G: D, H: N, I: D, K: D, L: D, M: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: N,

[switch to compact view]
Comments [show]
Publications
[hide] Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y
Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
Int J Cancer. 2003 Dec 10;107(5):757-63., 2003-12-10 [PMID:14566825] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mohrmann K, van Eijndhoven MA, Schinkel AH, Schellens JH
Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).
Cancer Chemother Pharmacol. 2005 Oct;56(4):344-50. Epub 2005 May 5., [PMID:15875186] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Cancer Sci. 2005 Aug;96(8):457-65., [PMID:16108826] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Perez-Tomas R
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Curr Med Chem. 2006;13(16):1859-76., [PMID:16842198] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hazai E, Bikadi Z
Homology modeling of breast cancer resistance protein (ABCG2).
J Struct Biol. 2008 Apr;162(1):63-74. Epub 2007 Dec 15., [PMID:18249138] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]